Related Experiment Video
Updated: May 28, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Botulinum Neurotoxin-A Inhibits Tumor Growth in a Triple-Negative Breast Cancer Preclinical Model
Evoli N Lopez1,2, Guadalupe Delgado-López2, Paola Maycotte3
1Laboratorio de Bioquímica y Biología Molecular, Centro de Química del Instituto de Ciencias (ICUAP), Benemérita Universidad Autónoma de Puebla, Puebla 72570, Mexico.
Abstract:
Triple-negative breast cancer (TNBC) continues to be a medical challenge requiring multiple treatment options. SV2A, a protein involved in vesicular release, has emerged as a promising biomarker for various cancers. Research shows that botulinum neurotoxin type A (BoNT/A), which binds to SV2A, the BoNT/A receptor, can inhibit the growth of prostate and breast cancer cells, suggesting its potential as an alternative treatment for breast cancer. The purpose of this study was to determine the potential of BoNT/A to inhibit tumor growth in a mouse preclinical model. BoNT/A was evaluated for its effects in an in vitro model employing 4T1 cells and in an in vivo model of orthotopically inoculated 4T1 cells in BALB/c mice. BoNT/A inhibited the proliferation of 4T1 cells, which express the SV2A protein; decreased tumor growth in the preclinical model; and decreased inflammation, associated with fewer blood neutrophils and monocytes, suggesting an immunomodulatory and anti-inflammatory effect. The effect of BoNT/A on the TNBC model supports its use as a repurposed drug for this type of aggressive cancer. Our results emphasize the significance of the SV2A receptor and its interaction with BoNT/A as promising therapeutic targets, particularly for TNBC.
Insights
Botulinum neurotoxin type A (BoNT/A) shows potential in treating triple-negative breast cancer (TNBC). This study found BoNT/A inhibited cancer cell growth and reduced tumor progression in preclinical models.
Area of Science:
- Oncology
- Neuroscience
- Immunology
Background:
- Triple-negative breast cancer (TNBC) presents a significant clinical challenge with limited therapeutic options.
- Synaptic vesicle glycoprotein 2A (SV2A) is implicated in cancer progression and serves as a receptor for botulinum neurotoxin type A (BoNT/A).
- BoNT/A has demonstrated anti-proliferative effects on prostate and breast cancer cells, indicating potential therapeutic applications.
Purpose of the Study:
- To investigate the efficacy of botulinum neurotoxin type A (BoNT/A) in inhibiting tumor growth within a triple-negative breast cancer (TNBC) preclinical model.
- To evaluate the direct effects of BoNT/A on cancer cell proliferation and tumor development in vivo.
- To explore the immunomodulatory and anti-inflammatory properties of BoNT/A in the context of TNBC.
Main Methods:
- In vitro assessment of BoNT/A's effect on 4T1 breast cancer cell proliferation.
- In vivo evaluation of BoNT/A's impact on orthotopically implanted 4T1 tumors in BALB/c mice.
- Analysis of inflammatory markers, including neutrophil and monocyte counts, in response to BoNT/A treatment.
Main Results:
- BoNT/A significantly inhibited the proliferation of SV2A-expressing 4T1 breast cancer cells in vitro.
- BoNT/A treatment led to a reduction in tumor growth in the preclinical TNBC mouse model.
- BoNT/A demonstrated anti-inflammatory effects, evidenced by decreased neutrophil and monocyte populations.
Conclusions:
- Botulinum neurotoxin type A (BoNT/A) exhibits therapeutic potential against triple-negative breast cancer (TNBC) by inhibiting tumor growth and inflammation.
- The interaction between SV2A and BoNT/A represents a promising target for novel cancer therapies.
- BoNT/A may be considered a repurposed drug for treating aggressive cancers like TNBC.
